Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATR | Q13535 | 1/20 | 0.41 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.36 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.36 |
| ▸ | MAPKAPK2 | P49137 | 3/20 | 0.35 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.35 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.35 |
| ▸ | METAP1 | P53582 | 1/20 | 0.35 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.34 |
| ▸ | KCNQ4 | P56696 | 1/20 | 0.34 |
| ▸ | KCNQ5 | Q9NR82 | 1/20 | 0.34 |
| ▸ | STK17B | O94768 | 1/20 | 0.34 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.34 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.34 |
| ▸ | RORC | P51449 | 2/20 | 0.34 |
| ▸ | SYK | P43405 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26894606 | 0.88 | ATR (0.41) | ATRP2RX3AAK1MAPKAPK2CYP17A1 | |
| SCHEMBL29936130 | 0.88 | ATR (0.41) | ATRP2RX3AAK1MAPKAPK2CYP17A1 | |
| SCHEMBL30722754 | 0.87 | ATR (0.40) | ATRP2RX3AAK1MAPKAPK2CYP17A1 | |
| SCHEMBL29143532 | 0.85 | ATR (0.42) | ATRP2RX3AAK1MAPKAPK2METAP1 | |
| SCHEMBL19960768 | 0.84 | ATR (0.43) | ATRP2RX3AAK1MAPKAPK2CYP17A1 | |
| SCHEMBL23291067 | 0.83 | ATR (0.42) | ATRP2RX3AAK1MAPKAPK2CYP17A1 | |
| SCHEMBL30038835 | 0.83 | ATR (0.42) | ATRP2RX3AAK1MAPKAPK2CYP17A1 | |
| SCHEMBL2019695 | 0.83 | ATR (0.42) | ATRP2RX3AAK1MAPKAPK2CYP17A1 | |
| SCHEMBL21789258 | 0.82 | ATR (0.41) | ATRP2RX3AAK1MAPKAPK2CYP17A1 | |
| SCHEMBL29936019 | 0.80 | ATR (0.40) | ATRP2RX3AAK1MAPKAPK2CYP17A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4551575-A2 | TREM2 MODULATORS | Muna Therapeutics ApS (DK) | 2025-05-14 | — | — | EP | disclosed |
| CN-119403806-A | TREM2 modulators | 穆纳治疗有限公司 | 2025-02-07 | — | — | CN | disclosed |
| US-20240327435-A1 | AMINO-SUBSTITUTED HETEROCYCLES FOR TREATING CANCERS WITH EGFR MUTATIONS | NUVALENT, INC. | 2024-10-03 | — | — | US | disclosed |
| CN-118459485-A | Amino-substituted heterocycles for the treatment of cancers with EGFR mutations | 纽威伦特公司 | 2024-08-09 | — | — | CN | disclosed |
| US-12037346-B2 | Amino-substituted heteroaryls for treating cancers with EGFR mutations | NUVALENT, INC. (US) | 2024-07-16 | — | — | US | disclosed |
| US-12037346-B2 | Amino-substituted heteroaryls for treating cancers with EGFR mutations | NUVALENT, INC. (US) | 2024-07-16 | — | — | US | disclosed |
| EP-4323356-A1 | AMINO-SUBSTITUTED HETEROCYCLES FOR TREATING CANCERS WITH EGFR MUTATIONS | Nuvalent, Inc. (US) | 2024-02-21 | — | — | EP | disclosed |
| CN-117500803-A | Amino-substituted heterocycles for the treatment of cancers with EGFR mutations | 纽威伦特公司 | 2024-02-02 | — | — | CN | disclosed |
| WO-2024008722-A2 | TREM2 MODULATORS | MUNA THERAPEUTICS APS (DK) | 2024-01-11 | — | — | WO | disclosed |
| WO-2024008722-A2 | TREM2 MODULATORS | MUNA THERAPEUTICS APS (DK) | 2024-01-11 | — | — | WO | disclosed |
| WO-2022221227-A9 | AMINO-SUBSTITUTED HETEROCYCLES FOR TREATING CANCERS WITH EGFR MUTATIONS | NUVALENT, INC. (US) | 2023-11-30 | — | — | WO | disclosed |
| WO-2022221227-A9 | AMINO-SUBSTITUTED HETEROCYCLES FOR TREATING CANCERS WITH EGFR MUTATIONS | NUVALENT, INC. (US) | 2023-11-30 | — | — | WO | disclosed |
| US-20220363696-A1 | AMINO-SUBSTITUTED HETEROCYCLES FOR TREATING CANCERS WITH EGFR MUTATIONS | NUVALENT, INC. | 2022-11-17 | — | — | US | disclosed |
| WO-2022221227-A1 | AMINO-SUBSTITUTED HETEROCYCLES FOR TREATING CANCERS WITH EGFR MUTATIONS | NUVALENT, INC. (US) | 2022-10-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12037346-B2 | Amino-substituted heteroaryls for treating cancers with EGFR mutations | EGFR, ERBB2, ERBB3 | ATR 573/4885P2RX3 3439/4885AAK1 2380/4885 |
| US-20220363696-A1 | AMINO-SUBSTITUTED HETEROCYCLES FOR TREATING CANCERS WITH EGFR MUTATIONS | EGFR, ERBB2, ERBB4 | ATR 525/4885P2RX3 2010/4885AAK1 989/4885 |
| US-20240327435-A1 | AMINO-SUBSTITUTED HETEROCYCLES FOR TREATING CANCERS WITH EGFR MUTATIONS | EGFR, ERBB2, ERBB4 | ATR 525/4885P2RX3 2010/4885AAK1 989/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.